AKT1 and lymphoma: According to a recent study, sorafenib showed anti-lymphoma activity in lymphoma cell lines by reducing phosphorylation in the PI3K/Akt and MAPK signaling pathways and thus inducing cell death176, indicating that sorafenib shows the potential to inhibit the activity of antitumor immune cells.